Orion Oyj (OTCMKTS:ORINY) Reaches New 12-Month High - Still a Buy?

Orion Oyj (OTCMKTS:ORINY - Get Free Report)'s share price reached a new 52-week high on Monday . The company traded as high as $32.15 and last traded at $32.15, with a volume of 550 shares traded. The stock had previously closed at $31.70.

Analyst Upgrades and Downgrades

Separately, Nordea Equity Research lowered shares of Orion Oyj to a "hold" rating in a research report on Tuesday, February 4th.

Orion Oyj Trading Up 1.4 %

The business has a 50 day simple moving average of $29.59 and a 200 day simple moving average of $26.26. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41. The company has a market cap of $8.66 billion, a price-to-earnings ratio of 24.35 and a beta of 0.17.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The company reported $0.23 earnings per share (EPS) for the quarter. The company had revenue of $373.03 million for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. As a group, equities analysts forecast that Orion Oyj will post 1.18 EPS for the current year.

Orion Oyj Increases Dividend

The company also recently announced a dividend, which was paid on Tuesday, April 29th. Stockholders of record on Monday, April 7th were given a dividend of $0.4478 per share. The ex-dividend date was Monday, April 7th. This is an increase from Orion Oyj's previous dividend of $0.24. Orion Oyj's payout ratio is presently 24.43%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.